PLAY PODCASTS
Expert Insight on Key Data From WCLC 2020 in Early-Stage Lung Cancer
Episode 36

Expert Insight on Key Data From WCLC 2020 in Early-Stage Lung Cancer

In this podcast episode, listen to Jamie E. Chaft, MD, discuss her thoughts on new data and studies focused on early-stage NSCLC presented at WCLC 2020.

Decera Clinical Education Oncology Podcast · Jamie E. Chaft MD

February 24, 202115m 12s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:

  • Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinib
  • An analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistance
  • FDG PET/CT adaptive radiotherapy in RTOG 1106
  • The TALENT study in Taiwan screening nonsmokers for lung cancer

Presenter:

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Content supported by educational grants from Amgen; Bristol-Myers Squibb; Ipsen Biopharmaceuticals; Janssen Pharmaceutica NV; Jazz Pharmaceuticals; Regeneron Pharmaceuticals, Inc. & Sanofi Genzyme; and Takeda Oncology.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
http://bit.ly/2NzE6X6


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

ercc1thymidine synthaseosimertinibcrtadaurafdgnsclcearly stagertadaptivertog 1106itacalung cancertalentpetjamie e. chaft mdchemoradiotherapychemotherapyradiotherapy